ACTIVATE: Panobinostat and Pegylated Interferon-alpha2a in HIV-1

Phase 2, randomised, open-label trial of panobinostat in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Occurrence of Grade >= 1 Adverse Events at 28 days and Change in CD4 T Cell-Associated Proviral HIV-1 DNA From Baseline at 4 weeks. Started May 2016; status: completed.